High Fidelity Drug Discovery
– Get an early lead
DNA encoded library screening in living cells
DELs in Cells – Unique offering by Vipergen
High success rate and low attrition rate – screening is performed under physiologically relevant conditionsBroad target space and short TAT – no need for purified target protein!
News
Vipergen releases DELs in Cells EXPRESS for Faster Drug Discovery
Vipergen introduces DELs in Cells EXPRESS, a novel service streamlining drug discovery.
Just provide the target protein sequence, and Vipergen handles the rest, delivering resynthesized hit compounds for further testing and validation within 30 business days.
The process, integrating the expression of the target protein and optimized DNA encoded libraries, ensures a swift turnaround without compromising success.
An ideal choice for projects requiring rapid progress, even when purified target protein is not readily available.
Meet us at
Drug Discovery Chemistry
San Diego, US, April 1-4
Vipergen presents a poster entitled ‘DELs in Cells: Turn-Around-Time Optimized’
EFMC-ACSMEDI Medicinal Chemistry Frontiers 2024
Utrecht, the Netherlands, April 8 to 11
Vipergen gives a talk entitled ‘DELs in Cells – Direct Screening for Molecular Glue’, and presents a poster entitled ‘DELs in Cells: Turn-Around-Time Optimized’
World-leading provider of small molecule drug discovery services based on DNA-encoded library technologies
Vipergen is finding tractable hits/leads for your pharmaceutical relevant targets, using three proprietary 2nd and 3rd generation DEL technologies.
Vipergen is offering different business models, including simple Fee-For-Service.
Do you have an inquiry?
Improve the starting point for lead optimization with Vipergen’s cutting-edge technologies.
Experience our unique approach to challenging targets. Ready to transform your research? Contact us today and explore partnership opportunities.
What we do
Vipergen revolutionizes drug discovery by screening for novel molecules directly in living cells, providing the tool to target complex molecular entities, improve hit rates, and develop effective pharmaceuticals.
Our approach prioritizes physiological relevance, ensuring a higher success rate and lower attrition rates in drug development.
We excel in finding the right molecular keys for a variety of complex biological locks.
How we do it
Our advanced technology allows us to conduct screenings in living cells, increasing the target space and reducing turnaround time significantly.
Unlike traditional methods, our process does not require a purified version of the target protein, enabling us to handle even the most challenging targets with ease and to initiate screenings more rapidly.
Who we are
Vipergen stands as a pioneer in the biotech and pharmaceutical industry, driven by a commitment to innovation and excellence.
Our team of highly qualified professionals brings together extensive expertise in chemistry and biology.
We are recognized for our unique ability to address complex drug discovery challenges that are beyond the reach of conventional approaches.
Cellular Binder Trap Enrichment (cBTE)
● 3rd generation screening technology
● Screening inside a living cell (unique capability)
● Physiologically relevant conditions
● Lower attrition rate
● No need for purified target protein (unique capability)
● Broader protein target space
● Multiplexing (unique capability)
Binder Trap Enrichment (BTE)
● 2nd generation screening technology
● Solution based (homogenous assay)
● No matrix binders
● No target denaturation by immobilization
● Low false positive rate
● Multiplexing (unique capability)
YoctoReactor (yR)
● 2nd generation library synthesis technology
● Chemical diversity by building blocks
● Physicochemical properties kept in check
● 100% match between code and compound
● Purification after each synthesis step (unique capability)
● Low false positive rate